Home » Topics » Regulatory » EMA

EMA
RSS

EMA approves pediatric investigation plan for TiGenix's Cx-601

Sep. 9, 2014

European orphan drug designations for CER-001 in apoA-I and ABCA1 deficiencies

Sep. 3, 2014

ALN-AT3 receives orphan drug designations in the E.U.

Aug. 8, 2014

NeuroDerm's ND-0612H eligible for EMA's centralized procedure

Aug. 7, 2014

U.S. and E.U. orphan drug designations for AbbVie's ABT-414 for glioblastoma multiforme

Aug. 5, 2014

Intravenous posaconazole recommended for approval in E.U.

Aug. 1, 2014

EMA accepts Eisai's request for accelerated assessment of lenvatinib

Aug. 1, 2014

EMA committee recommends approval of Baraclude for pediatric patients with HBV

July 30, 2014

Novo Nordisk receives positive CHMP opinion on Xultophy

July 29, 2014

CHMP recommends extension of Ozurdex indication in diabetic macular edema

July 28, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.